Controlling the Mdm2-Mdmx-p53 circuit

Pharmaceuticals

Volumn 3, Issue 5, 2010, Pages 1576-1593

  Waning, David L ^a   Lehman, Jason A ^a   Batuello, Christopher N ^a   Mayo, Lindsey D ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Kinase inhibitor; Mdm2; Mdmx; P53; Phosphorylation

Indexed keywords

2 MORPHOLINO 6 (1 THIANTHRENYL) 4 PYRANONE; 2 MORPHOLINO 8 PHENYLCHROMONE; 2 [2 METHOXY 5 (2,4,6 TRIMETHOXYSTYRYLSULFONYLMETHYL)ANILINO]PROPIONIC ACID; ABELSON KINASE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; APIGENIN; AT 7519; ATM PROTEIN; AZD 7762; CP 466722; CURCUMIN; DASATINIB; IMATINIB; INGENOL 3 ANGELATE; KU 60019; LAPATINIB; MAKASSARIC ACID; MIDOSTAURIN; N [5 (5 TERT BUTYL 2 OXAZOLYLMETHYLTHIO) 2 THIAZOLYL]ISONIPECOTAMIDE; NILOTINIB; NU 7422; NU 7441; PROTEIN KINASE INHIBITOR; PROTEIN MDM2; PROTEIN MDMX; PROTEIN P53; PYRAZINOINDOLONE; SAFINGOL; SUBERSIC ACID; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BLOOD CELL COUNT; BREAST ADENOCARCINOMA; CHRONIC MYELOID LEUKEMIA; DNA DAMAGE; DRUG BINDING SITE; DRUG DESIGN; DRUG PROTEIN BINDING; DRUG TARGETING; ENZYME REACTIVATION; HUMAN; LEYDIG CELL TUMOR; MOLECULAR MECHANICS; NONHUMAN; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; PROTEIN SYNTHESIS INHIBITION; PROTEIN SYNTHESIS REGULATION; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; WILD TYPE;

EID: 77954920885     PISSN: None     EISSN: 14248247     Source Type: Journal    
DOI: 10.3390/ph3051576     Document Type: Review

References (109)

1. Sionov, R. V.; Haupt, Y. The cellular response to p53: The decision between life and death. Oncogene 1999, 18, 6145-6157.
2. Vousden, K. H.; Lane, D. P. p53 in health and disease. Nat. Rev. Mol. Cell Biol. 2007, 8, 275-283.
3. Haupt, Y.; Maya, R.; Kazaz, A.; Oren, M. Mdm2 promotes the rapid degradation of p53. Nature 1997, 387, 296-299.
4. Honda, R.; Tanaka, H.; Yasuda, H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett. 1997, 420, 25-27.
5. Kubbutat, M. H.; Jones, S. N.; Vousden, K. H. Regulation of p53 stability by Mdm2. Nature 1997, 387, 299-303.
6. Shvarts, A.; Steegenga, W. T.; Riteco, N.; van Laar, T.; Dekker, P.; Bazuine, M.; van Ham, R. C.; van der Houven van Oordt, W.; Hateboer, G.; van der Eb, A. J.; Jochemsen, A. G. MDMX: A novel p53-binding protein with some functional properties of MDM2. EMBO J. 1996, 15, 5349-5357.
7. Chen, J.; Marechal, V.; Levine, A. J. Mapping of the p53 and mdm-2 interaction domains. Mol. Cell Biol. 1993, 13, 4107-4114.
8. Oliner, J. D.; Pietenpol, J. A.; Thiagalingam, S.; Gyuris, J.; Kinzler, K. W.; Vogelstein, B., Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 1993, 362, 857-860.
9. Momand, J.; Zambetti, G. P.; Olson, D. C.; George, D.; Levine, A. J. The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992, 69, 1237-1245.
10. Hay, T. J.; Meek, D. W. Multiple sites of in vivo phosphorylation in the MDM2 oncoprotein cluster within two important functional domains. FEBS Lett. 2000, 478, 183-186.
11. Meek, D. W.; Hupp, T. R. The regulation of MDM2 by multisite phosphorylation-Opportunities for molecular-based intervention to target tumours? Semin. Cancer Biol. 2009.
12. Kruse, J. P.; Gu, W. Modes of p53 regulation. Cell 2009, 137, 609-622.
13. Vousden, K. H.; Prives, C. Blinded by the Light: The Growing Complexity of p53. Cell 2009, 137, 413-431.
14. Badciong, J. C.; Haas, A. L. MdmX is a RING finger ubiquitin ligase capable of synergistically enhancing Mdm2 ubiquitination. J. Biol. Chem. 2002, 277, 49668-49675.
15. Harris, S. L.; Levine, A. J. The p53 pathway: positive and negative feedback loops. Oncogene 2005, 24, 2899-2908.
16. Kastan, M. B.; Bartek, J. Cell-cycle checkpoints and cancer. Nature 2004, 432, 316-323.
17. Shiloh, Y. ATM and related protein kinases: safeguarding genome integrity. Nat. Rev. Cancer 2003, 3, 155-168.
18. Zhou, B. B.; Elledge, S. J. The DNA damage response: Putting checkpoints in perspective. Nature 2000, 408, 433-439.
19. Meek, D. W. Tumour suppression by p53: A role for the DNA damage response? Nat. Rev. Cancer 2009, 9, 714-723.
20. Prives, C. Signaling to p53: Breaking the MDM2-p53 circuit. Cell 1998, 95, 5-8.
21. Bode, A. M.; Dong, Z. Post-translational modification of p53 in tumorigenesis. Nat. Rev. Cancer 2004, 4, 793-805.
22. Blaydes, J. P.; Luciani, M. G.; Pospisilova, S.; Ball, H. M.; Vojtesek, B.; Hupp, T. R. Stoichiometric phosphorylation of human p53 at Ser315 stimulates p53-dependent transcription. J. Biol. Chem. 2001, 276, 4699-4708.
23. Huang, C.; Ma, W. Y.; Maxiner, A.; Sun, Y.; Dong, Z. p38 kinase mediates UV-induced phosphorylation of p53 protein at serine 389. J. Biol. Chem. 1999, 274, 12229-12235.
24. Bech-Otschir, D.; Kraft, R.; Huang, X.; Henklein, P.; Kapelari, B.; Pollmann, C.; Dubiel, W. COP9 signalosome-specific phosphorylation targets p53 to degradation by the ubiquitin system. EMBO J. 2001, 20, 1630-1639.
25. Li, H. H.; Li, A. G.; Sheppard, H. M.; Liu, X. Phosphorylation on Thr-55 by TAF1 mediates degradation of p53: a role for TAF1 in cell G1 progression. Mol. Cell 2004, 13, 867-878.
26. Gatti, A.; Li, H. H.; Traugh, J. A.; Liu, X. Phosphorylation of human p53 on Thr-55. Biochemistry 2000, 39, 9837-9842.
27. Waterman, M. J.; Stavridi, E. S.; Waterman, J. L.; Halazonetis, T. D. ATM-dependent activation of p53 involves dephosphorylation and association with 14-3-3 proteins. Nat. Genet. 1998, 19, 175-178.
28. Chernov, M. V.; Bean, L. J.; Lerner, N.; Stark, G. R. Regulation of ubiquitination and degradation of p53 in unstressed cells through C-terminal phosphorylation. J. Biol. Chem. 2001, 276, 31819-31824.
29. Shieh, S. Y.; Ikeda, M.; Taya, Y.; Prives, C. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell 1997, 91, 325-334.
30. Shieh, S. Y.; Ahn, J.; Tamai, K.; Taya, Y.; Prives, C. The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites. Genes. Dev. 2000, 14, 289-300.
31. Chao, C.; Hergenhahn, M.; Kaeser, M. D.; Wu, Z.; Saito, S.; Iggo, R.; Hollstein, M.; Appella, E.; Xu, Y. Cell type- and promoter-specific roles of Ser18 phosphorylation in regulating p53 responses. J. Biol. Chem. 2003, 278, 41028-41033.
32. Khosravi, R.; Maya, R.; Gottlieb, T.; Oren, M.; Shiloh, Y.; Shkedy, D. Rapid ATM-dependent phosphorylation of MDM2 precedes p53 accumulation in response to DNA damage. Proc. Natl. Acad. Sci. USA 1999, 96, 14973-14977.
33. Ashcroft, M.; Kubbutat, M. H.; Vousden, K. H. Regulation of p53 function and stability by phosphorylation. Mol. Cell Biol. 1999, 19, 1751-1758.
34. Dumaz, N.; Meek, D. W. Serine15 phosphorylation stimulates p53 transactivation but does not directly influence interaction with HDM2. EMBO J. 1999, 18, 7002-7010.
35. Bartek, J.; Falck, J.; Lukas, J. CHK2 kinase-A busy messenger. Nat. Rev. Mol. Cell Biol. 2001, 2, 877-886.
36. Tibbetts, R. S.; Brumbaugh, K. M.; Williams, J. M.; Sarkaria, J. N.; Cliby, W. A.; Shieh, S. Y.; Taya, Y.; Prives, C.; Abraham, R. T. A role for ATR in the DNA damage-induced phosphorylation of p53. Genes. Dev. 1999, 13, 152-157.
37. Sakaguchi, K.; Saito, S.; Higashimoto, Y.; Roy, S.; Anderson, C. W.; Appella, E. Damagemediated phosphorylation of human p53 threonine 18 through a cascade mediated by a casein 1- like kinase: Effect on Mdm2 binding. J. Biol. Chem. 2000, 275, 9278-9283.
38. Dumaz, N.; Milne, D. M.; Meek, D. W. Protein kinase CK1 is a p53-threonine 18 kinase which requires prior phosphorylation of serine 15. FEBS Lett. 1999, 463, 312-316.
39. Higashimoto, Y.; Saito, S.; Tong, X. H.; Hong, A.; Sakaguchi, K.; Appella, E.; Anderson, C. W. Human p53 is phosphorylated on serines 6 and 9 in response to DNA damage-inducing agents. J. Biol. Chem. 2000, 275, 23199-23203.
40. Knippschild, U.; Milne, D. M.; Campbell, L. E.; DeMaggio, A. J.; Christenson, E.; Hoekstra, M. F.; Meek, D. W. p53 is phosphorylated in vitro and in vivo by the delta and epsilon isoforms of casein kinase 1 and enhances the level of casein kinase 1 delta in response to topoisomerasedirected drugs. Oncogene 1997, 15, 1727-1736.
41. Buschmann, T.; Potapova, O.; Bar-Shira, A.; Ivanov, V. N.; Fuchs, S. Y.; Henderson, S.; Fried, V. A.; Minamoto, T.; Alarcon-Vargas, D.; Pincus, M. R.; Gaarde, W. A.; Holbrook, N. J.; Shiloh, Y.; Ronai, Z., Jun NH2-terminal kinase phosphorylation of p53 on Thr-81 is important for p53 stabilization and transcriptional activities in response to stress. Mol. Cell Biol. 2001, 21, 2743-2754.
42. Hofmann, T. G.; Moller, A.; Sirma, H.; Zentgraf, H.; Taya, Y.; Droge, W.; Will, H.; Schmitz, M. L. Regulation of p53 activity by its interaction with homeodomain-interacting protein kinase-2. Nat. Cell Biol. 2002, 4, 1-10.
43. D'Orazi, G.; Cecchinelli, B.; Bruno, T.; Manni, I.; Higashimoto, Y.; Saito, S.; Gostissa, M.; Coen, S.; Marchetti, A.; Del Sal, G.; Piaggio, G.; Fanciulli, M.; Appella, E.; Soddu, S. Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis. Nat. Cell Biol. 2002, 4, 11-19.
44. Mayo, L. D.; Turchi, J. J.; Berberich, S. J. Mdm-2 phosphorylation by DNA-dependent protein kinase prevents interaction with p53. Cancer Res. 1997, 57, 5013-5016.
45. Worrall, E. G.; Worrall, L.; Blackburn, E.; Walkinshaw, M.; Hupp, T. R. The effects of phosphomimetic lid mutation on the thermostability of the N-terminal domain of MDM2. J. Mol. Biol. 2010, 398, 414-428.
46. Blattner, C.; Hay, T.; Meek, D. W.; Lane, D. P. Hypophosphorylation of Mdm2 augments p53 stability. Mol. Cell Biol. 2002, 22, 6170-6182.
47. Hjerrild, M.; Milne, D.; Dumaz, N.; Hay, T.; Issinger, O. G.; Meek, D. Phosphorylation of murine double minute clone 2 (MDM2) protein at serine-267 by protein kinase CK2 in vitro and in cultured cells. Biochem. J. 2001, 355, 347-356.
48. Kawai, H.; Wiederschain, D.; Yuan, Z. M. Critical contribution of the MDM2 acidic domain to p53 ubiquitination. Mol. Cell Biol. 2003, 23, 4939-4947.
49. Yang, J.; Xu, Z. P.; Huang, Y.; Hamrick, H. E.; Duerksen-Hughes, P. J.; Yu, Y. N. ATM and ATR: Sensing DNA damage. World J. Gastroenterol. 2004, 10, 155-160.
50. Maya, R.; Balass, M.; Kim, S. T.; Shkedy, D.; Leal, J. F.; Shifman, O.; Moas, M.; Buschmann, T.; Ronai, Z.; Shiloh, Y.; Kastan, M. B.; Katzir, E.; Oren, M. ATM-dependent phosphorylation of Mdm2 on serine 395: Role in p53 activation by DNA damage. Genes Dev. 2001, 15, 1067-1077.
51. Cheng, Q.; Chen, L.; Li, Z.; Lane, W. S.; Chen, J. ATM activates p53 by regulating MDM2 oligomerization and E3 processivity. EMBO J. 2009, 28, 3857-3867.
52. Shinozaki, T.; Nota, A.; Taya, Y.; Okamoto, K. Functional role of Mdm2 phosphorylation by ATR in attenuation of p53 nuclear export. Oncogene 2003, 22, 8870-8880.
53. Brasher, B. B.; Van Etten, R. A. c-Abl has high intrinsic tyrosine kinase activity that is stimulated by mutation of the Src homology 3 domain and by autophosphorylation at two distinct regulatory tyrosines. J. Biol. Chem. 2000, 275, 35631-35637.
54. Shafman, T.; Khanna, K. K.; Kedar, P.; Spring, K.; Kozlov, S.; Yen, T.; Hobson, K.; Gatei, M.; Zhang, N.; Watters, D.; Egerton, M.; Shiloh, Y.; Kharbanda, S.; Kufe, D.; Lavin, M. F. Interaction between ATM protein and c-Abl in response to DNA damage. Nature 1997, 387, 520-523.
55. Kharbanda, S.; Ren, R.; Pandey, P.; Shafman, T. D.; Feller, S. M.; Weichselbaum, R. R.; Kufe, D. W. Activation of the c-Abl tyrosine kinase in the stress response to DNA-damaging agents. Nature 1995, 376, 785-788.
56. Dias, S. S.; Milne, D. M.; Meek, D. W. c-Abl phosphorylates Hdm2 at tyrosine 276 in response to DNA damage and regulates interaction with ARF. Oncogene 2006, 25, 6666-6671.
57. Goldberg, Z.; Vogt Sionov, R.; Berger, M.; Zwang, Y.; Perets, R.; Van Etten, R. A.; Oren, M.; Taya, Y.; Haupt, Y. Tyrosine phosphorylation of Mdm2 by c-Abl: implications for p53 regulation. EMBO J. 2002, 21, 3715-3727.
58. Chen, L.; Gilkes, D. M.; Pan, Y.; Lane, W. S.; Chen, J. ATM and Chk2-dependent phosphorylation of MDMX contribute to p53 activation after DNA damage. EMBO J. 2005, 24, 3411-3422.
59. Pereg, Y.; Lam, S.; Teunisse, A.; Biton, S.; Meulmeester, E.; Mittelman, L.; Buscemi, G.; Okamoto, K.; Taya, Y.; Shiloh, Y.; Jochemsen, A. G. Differential roles of ATM- and Chk2- mediated phosphorylations of Hdmx in response to DNA damage. Mol. Cell Biol. 2006, 26, 6819-6831.
60. Okamoto, K.; Kashima, K.; Pereg, Y.; Ishida, M.; Yamazaki, S.; Nota, A.; Teunisse, A.; Migliorini, D.; Kitabayashi, I.; Marine, J. C.; Prives, C.; Shiloh, Y.; Jochemsen, A. G.; Taya, Y. DNA damage-induced phosphorylation of MdmX at serine 367 activates p53 by targeting MdmX for Mdm2-dependent degradation. Mol. Cell Biol. 2005, 25, 9608-9620.
61. LeBron, C.; Chen, L.; Gilkes, D. M.; Chen, J. Regulation of MDMX nuclear import and degradation by Chk2 and 14-3-3. EMBO J. 2006, 25, 1196-1206.
62. Wang, Y. V.; Leblanc, M.; Wade, M.; Jochemsen, A. G.; Wahl, G. M. Increased radioresistance and accelerated B cell lymphomas in mice with Mdmx mutations that prevent modifications by DNA-damage-activated kinases. Cancer Cell 2009, 16, 33-43.
63. Zuckerman, V.; Lenos, K.; Popowicz, G. M.; Silberman, I.; Grossman, T.; Marine, J. C.; Holak, T. A.; Jochemsen, A. G.; Haupt, Y. c-Abl phosphorylates Hdmx and regulates its interaction with p53. J. Biol. Chem. 2009, 284, 4031-4039.
64. Chen, L.; Li, C.; Pan, Y.; Chen, J. Regulation of p53-MDMX interaction by casein kinase 1 alpha. Mol. Cell Biol. 2005, 25, 6509-6520.
65. Zhang, J.; Yang, P. L.; Gray, N. S. Targeting cancer with small molecule kinase inhibitors. Nat. Rev. Cancer 2009, 9, 28-39.
66. Druker, B. J.; Tamura, S.; Buchdunger, E.; Ohno, S.; Segal, G. M.; Fanning, S.; Zimmermann, J.; Lydon, N. B. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr- Abl positive cells. Nat. Med. 1996, 2, 561-566.
67. Das, J.; Chen, P.; Norris, D.; Padmanabha, R.; Lin, J.; Moquin, R. V.; Shen, Z.; Cook, L. S.; Doweyko, A. M.; Pitt, S.; Pang, S.; Shen, D. R.; Fang, Q.; de Fex, H. F.; McIntyre, K. W.; Shuster, D. J.; Gillooly, K. M.; Behnia, K.; Schieven, G. L.; Wityak, J.; Barrish, J. C. 2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1- piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (dasatinib, BMS- 354825) as a potent pan-Src kinase inhibitor. J. Med. Chem. 2006, 49, 6819-6832.
68. Shah, N. P.; Tran, C.; Lee, F. Y.; Chen, P.; Norris, D.; Sawyers, C. L. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004, 305, 399-401.
69. Weisberg, E.; Manley, P.; Mestan, J.; Cowan-Jacob, S.; Ray, A.; Griffin, J. D. AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. Br. J. Cancer 2006, 94, 1765-1769.
70. Gumireddy, K.; Baker, S. J.; Cosenza, S. C.; John, P.; Kang, A. D.; Robell, K. A.; Reddy, M. V.; Reddy, E. P. A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance. Proc. Natl. Acad. Sci. USA 2005, 102, 1992-1997.
71. Hickson, I.; Zhao, Y.; Richardson, C. J.; Green, S. J.; Martin, N. M.; Orr, A. I.; Reaper, P. M.; Jackson, S. P.; Curtin, N. J.; Smith, G. C. Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM. Cancer Res. 2004, 64, 9152-9159.
72. Golding, S. E.; Rosenberg, E.; Valerie, N.; Hussaini, I.; Frigerio, M.; Cockcroft, X. F.; Chong, W. Y.; Hummersone, M.; Rigoreau, L.; Menear, K. A.; O'Connor, M. J.; Povirk, L. F.; van Meter, T.; Valerie, K. Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion. Mol. Cancer Ther. 2009, 8, 2894-2902.
73. Rainey, M. D.; Charlton, M. E.; Stanton, R. V.; Kastan, M. B. Transient inhibition of ATM kinase is sufficient to enhance cellular sensitivity to ionizing radiation. Cancer Res. 2008, 68, 7466-7474.
74. Heath, E. I.; Bible, K.; Martell, R. E.; Adelman, D. C.; Lorusso, P. M. A phase 1 study of SNS- 032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors. Invest. New Drugs 2008, 26, 59-65.
75. Santo, L.; Vallet, S.; Hideshima, T.; Cirstea, D.; Ikeda, H.; Pozzi, S.; Patel, K.; Okawa, Y.; Gorgun, G.; Perrone, G.; Calabrese, E.; Yule, M.; Squires, M.; Ladetto, M.; Boccadoro, M.; Richardson, P. G.; Munshi, N. C.; Anderson, K. C.; Raje, N. AT7519, a novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3beta activation and RNA polymerase II inhibition. Oncogene 2010, 29, 2325-2336.
76. Zabludoff, S. D.; Deng, C.; Grondine, M. R.; Sheehy, A. M.; Ashwell, S.; Caleb, B. L.; Green, S.; Haye, H. R.; Horn, C. L.; Janetka, J. W.; Liu, D.; Mouchet, E.; Ready, S.; Rosenthal, J. L.; Queva, C.; Schwartz, G. K.; Taylor, K. J.; Tse, A. N.; Walker, G. E.; White, A. M. AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies. Mol. Cancer Ther. 2008, 7, 2955-2966.
77. Kashishian, A.; Douangpanya, H.; Clark, D.; Schlachter, S. T.; Eary, C. T.; Schiro, J. G.; Huang, H.; Burgess, L. E.; Kesicki, E. A.; Halbrook, J. DNA-dependent protein kinase inhibitors as drug candidates for the treatment of cancer. Mol. Cancer Ther. 2003, 2, 1257-1264.
78. Zhao, Y.; Thomas, H. D.; Batey, M. A.; Cowell, I. G.; Richardson, C. J.; Griffin, R. J.; Calvert, A. H.; Newell, D. R.; Smith, G. C.; Curtin, N. J. Preclinical evaluation of a potent novel DNAdependent protein kinase inhibitor NU7441. Cancer Res. 2006, 66, 5354-5362.
79. Hardcastle, I. R.; Cockcroft, X.; Curtin, N. J.; El-Murr, M. D.; Leahy, J. J.; Stockley, M.; Golding, B. T.; Rigoreau, L.; Richardson, C.; Smith, G. C.; Griffin, R. J. Discovery of potent chromen-4-one inhibitors of the DNA-dependent protein kinase (DNA-PK) using a smallmolecule library approach. J. Med. Chem. 2005, 48, 7829-7846.
80. Vlahos, C. J.; Matter, W. F.; Hui, K. Y.; Brown, R. F. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J. Biol. Chem. 1994, 269, 5241-5248.
81. Burris, H. A., III. Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib. Oncologist 2004, 9 (Suppl. 3), 10-15.
82. Bennett, B. L.; Sasaki, D. T.; Murray, B. W.; O'Leary, E. C.; Sakata, S. T.; Xu, W.; Leisten, J. C.; Motiwala, A.; Pierce, S.; Satoh, Y.; Bhagwat, S. S.; Manning, A. M.; Anderson, D. W. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc. Natl. Acad. Sci. USA 2001, 98, 13681-13686.
83. Goldberg, D. R.; Choi, Y.; Cogan, D.; Corson, M.; DeLeon, R.; Gao, A.; Gruenbaum, L.; Hao, M. H.; Joseph, D.; Kashem, M. A.; Miller, C.; Moss, N.; Netherton, M. R.; Pargellis, C. P.; Pelletier, J.; Sellati, R.; Skow, D.; Torcellini, C.; Tseng, Y. C.; Wang, J.; Wasti, R.; Werneburg, B.; Wu, J. P.; Xiong, Z. Pyrazinoindolone inhibitors of MAPKAP-K2. Bioorg. Med. Chem. Lett. 2008, 18, 938-941.
84. Williams, D. E.; Telliez, J. B.; Liu, J.; Tahir, A.; van Soest, R.; Andersen, R. J. Meroterpenoid MAPKAP (MK2) inhibitors isolated from the indonesian marine sponge Acanthodendrilla sp. J. Nat. Prod. 2004, 67, 2127-2129.
85. Gillespie, S. K.; Zhang, X. D.; Hersey, P. Ingenol 3-angelate induces dual modes of cell death and differentially regulates tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in melanoma cells. Mol. Cancer Ther. 2004, 3, 1651-1658.
86. Kedei, N.; Lundberg, D. J.; Toth, A.; Welburn, P.; Garfield, S. H.; Blumberg, P. M. Characterization of the interaction of ingenol 3-angelate with protein kinase C. Cancer Res. 2004, 64, 3243-3255.
87. Millward, M. J.; House, C.; Bowtell, D.; Webster, L.; Olver, I. N.; Gore, M.; Copeman, M.; Lynch, K.; Yap, A.; Wang, Y.; Cohen, P. S.; Zalcberg, J. The multikinase inhibitor midostaurin (PKC412A) lacks activity in metastatic melanoma: a phase IIA clinical and biologic study. Br. J. Cancer 2006, 95, 829-834.
88. Coward, J.; Ambrosini, G.; Musi, E.; Truman, J. P.; Haimovitz-Friedman, A.; Allegood, J. C.; Wang, E.; Merrill, A. H., Jr.; Schwartz, G. K. Safingol (L-threo-sphinganine) induces autophagy in solid tumor cells through inhibition of PKC and the PI3-kinase pathway. Autophagy 2009, 5, 184-193.
89. Ujiki, M. B.; Ding, X. Z.; Salabat, M. R.; Bentrem, D. J.; Golkar, L.; Milam, B.; Talamonti, M. S.; Bell, R. H., Jr.; Iwamura, T.; Adrian, T. E. Apigenin inhibits pancreatic cancer cell proliferation through G2/M cell cycle arrest. Mol. Cancer 2006, 5, 76.
90. Noble, M. E.; Endicott, J. A.; Johnson, L. N. Protein kinase inhibitors: insights into drug design from structure. Science 2004, 303, 1800-1805.
91. Martins, C. P.; Brown-Swigart, L.; Evan, G. I. Modeling the therapeutic efficacy of p53 restoration in tumors. Cell 2006, 127, 1323-1334.
92. Ventura, A.; Kirsch, D. G.; McLaughlin, M. E.; Tuveson, D. A.; Grimm, J.; Lintault, L.; Newman, J.; Reczek, E. E.; Weissleder, R.; Jacks, T. Restoration of p53 function leads to tumour regression in vivo. Nature 2007, 445, 661-665.
93. Terzian, T.; Wang, Y.; Van Pelt, C. S.; Box, N. F.; Travis, E. L.; Lozano, G. Haploinsufficiency of Mdm2 and Mdm4 in tumorigenesis and development. Mol. Cell. Biol. 2007, 27, 5479-5485.
94. Toledo, F.; Wahl, G. M. Regulating the p53 pathway: In vitro hypotheses, in vivo veritas. Nat. Rev. Cancer 2006, 6, 909-923.
95. Oliner, J. D.; Kinzler, K. W.; Meltzer, P. S.; George, D. L.; Vogelstein, B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 1992, 358, 80-83.
96. Jones, S. N.; Hancock, A. R.; Vogel, H.; Donehower, L. A.; Bradley, A. Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis. Proc. Natl. Acad. Sci. USA 1998, 95, 15608-15612.
97. Bond, G. L.; Hu, W.; Bond, E. E.; Robins, H.; Lutzker, S. G.; Arva, N. C.; Bargonetti, J.; Bartel, F.; Taubert, H.; Wuerl, P.; Onel, K.; Yip, L.; Hwang, S. J.; Strong, L. C.; Lozano, G.; Levine, A. J. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 2004, 119, 591-602.
98. Alt, J. R.; Greiner, T. C.; Cleveland, J. L.; Eischen, C. M. Mdm2 haplo-insufficiency profoundly inhibits Myc-induced lymphomagenesis. EMBO J. 2003, 22, 1442-1450.
99. Savage, D. G.; Antman, K. H. Imatinib mesylate-A new oral targeted therapy. N. Engl. J. Med. 2002, 346, 683-693.
100. Faderl, S.; Talpaz, M.; Estrov, Z.; O'Brien, S.; Kurzrock, R.; Kantarjian, H. M. The biology of chronic myeloid leukemia. N. Engl. J. Med. 1999, 341, 164-172.
101. Kantarjian, H.; Sawyers, C.; Hochhaus, A.; Guilhot, F.; Schiffer, C.; Gambacorti-Passerini, C.; Niederwieser, D.; Resta, D.; Capdeville, R.; Zoellner, U.; Talpaz, M.; Druker, B.; Goldman, J.; O'Brien, S. G.; Russell, N.; Fischer, T.; Ottmann, O.; Cony-Makhoul, P.; Facon, T.; Stone, R.; Miller, C.; Tallman, M.; Brown, R.; Schuster, M.; Loughran, T.; Gratwohl, A.; Mandelli, F.; Saglio, G.; Lazzarino, M.; Russo, D.; Baccarani, M.; Morra, E. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N. Engl. J. Med. 2002, 346, 645-652.
102. Kantarjian, H. M.; Talpaz, M.; O'Brien, S.; Smith, T. L.; Giles, F. J.; Faderl, S.; Thomas, D. A.; Garcia-Manero, G.; Issa, J. P.; Andreeff, M.; Kornblau, S. M.; Koller, C.; Beran, M.; Keating, M.; Rios, M. B.; Shan, J.; Resta, D.; Capdeville, R.; Hayes, K.; Albitar, M.; Freireich, E. J.; Cortes, J. E. Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: Follow-up results. Clin. Cancer Res. 2002, 8, 2177-2187.
103. Pearson, M. A.; Fabbro, D. Targeting protein kinases in cancer therapy: A success? Expert Rev. Anticancer Ther. 2004, 4, 1113-1124.
104. Arora, A.; Scholar, E. M. Role of tyrosine kinase inhibitors in cancer therapy. J. Pharmacol. Exp. Ther. 2005, 315, 971-979.
105. Gorre, M. E.; Mohammed, M.; Ellwood, K.; Hsu, N.; Paquette, R.; Rao, P. N.; Sawyers, C. L. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001, 293, 876-880.
106. Froehner, M.; Beuthien-Baumann, B.; Dittert, D. D.; Schuler, U.; Wirth, M. P. Lack of efficacy of imatinib in a patient with metastatic Leydig cell tumor. Cancer Chemother. Pharmacol. 2006, 58, 716-718.
107. Samoszuk, M.; Corwin, M. A. Acceleration of tumor growth and peri-tumoral blood clotting by imatinib mesylate (Gleevec). Int. J. Cancer 2003, 106, 647-652.
108. Basciani, S.; Brama, M.; Mariani, S.; De Luca, G.; Arizzi, M.; Vesci, L.; Pisano, C.; Dolci, S.; Spera, G.; Gnessi, L. Imatinib mesylate inhibits Leydig cell tumor growth: Evidence for in vitro and in vivo activity. Cancer Res. 2005, 65, 1897-1903.
109. Joensuu, H.; Roberts, P. J.; Sarlomo-Rikala, M.; Andersson, L. C.; Tervahartiala, P.; Tuveson, D.; Silberman, S.; Capdeville, R.; Dimitrijevic, S.; Druker, B.; Demetri, G. D. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N. Engl. J. Med. 2001, 344, 1052-1056.